News | January 22, 2022
USFDA expands use of Remdesivir for Covid-19
Previously, the use of the drug was limited to patients requiring hospitalization
Previously, the use of the drug was limited to patients requiring hospitalization
Go-ahead for pivotal clinical trial which is expected to commence by March
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Subscribe To Our Newsletter & Stay Updated
